See more : Guardant Health, Inc. (GH) Income Statement Analysis – Financial Results
Complete financial analysis of Cardlytics, Inc. (CDLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardlytics, Inc., a leading company in the Advertising Agencies industry within the Communication Services sector.
You may be interested
- Korea Electric Power Corporation (015760.KS) Income Statement Analysis – Financial Results
- O’Pay Electronic Payment Co., Ltd. (6878.TWO) Income Statement Analysis – Financial Results
- Smart Eye AB (publ) (SMTEF) Income Statement Analysis – Financial Results
- DoorDash, Inc. (DASH) Income Statement Analysis – Financial Results
- Wharf (Holdings) Limited (WARFF) Income Statement Analysis – Financial Results
Cardlytics, Inc. (CDLX)
About Cardlytics, Inc.
Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 309.20M | 298.54M | 267.12M | 186.89M | 210.43M | 150.68M | 130.37M | 112.82M | 77.63M |
| Cost of Revenue | 178.83M | 185.91M | 163.78M | 123.62M | 130.97M | 96.00M | 80.26M | 72.41M | 52.49M |
| Gross Profit | 130.38M | 112.63M | 103.34M | 63.27M | 79.46M | 54.68M | 50.11M | 40.41M | 25.14M |
| Gross Profit Ratio | 42.17% | 37.73% | 38.69% | 33.86% | 37.76% | 36.29% | 38.44% | 35.82% | 32.38% |
| Research & Development | 51.35M | 54.44M | 38.10M | 17.53M | 11.70M | 16.21M | 12.15M | 13.90M | 11.60M |
| General & Administrative | 58.81M | 81.45M | 66.22M | 46.53M | 36.72M | 34.23M | 20.10M | 21.36M | 18.20M |
| Selling & Marketing | 57.43M | 74.75M | 66.00M | 45.31M | 43.83M | 41.88M | 31.93M | 31.26M | 32.78M |
| SG&A | 116.24M | 156.19M | 132.22M | 91.84M | 80.55M | 76.11M | 52.03M | 52.62M | 50.98M |
| Other Expenses | 98.46M | 37.54M | 29.87M | 7.83M | 4.54M | -2.10M | 6.28M | -13.26M | -432.00K |
| Operating Expenses | 266.05M | 248.17M | 200.19M | 117.20M | 96.78M | 95.60M | 67.21M | 70.74M | 64.78M |
| Cost & Expenses | 444.87M | 434.08M | 363.97M | 240.82M | 227.76M | 191.60M | 147.46M | 143.15M | 117.27M |
| Interest Income | 3.85M | 1.44M | 297.00K | 440.00K | 829.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.18M | 2.56M | 12.56M | 3.05M | 1.38M | 3.26M | 8.24M | 0.00 | 0.00 |
| Depreciation & Amortization | 29.52M | 43.74M | 33.66M | 12.42M | 7.40M | 3.28M | 3.03M | 4.22M | 2.19M |
| EBITDA | -99.00M | -418.98M | -89.91M | -39.51M | -12.79M | -45.97M | -8.37M | -24.00M | -37.45M |
| EBITDA Ratio | -32.02% | -30.75% | -22.91% | -22.65% | -6.08% | -20.49% | -10.35% | -0.15% | -49.41% |
| Operating Income | -135.67M | -135.54M | -96.85M | -53.92M | -17.33M | -40.92M | -17.10M | -56.23M | -39.64M |
| Operating Income Ratio | -43.88% | -45.40% | -36.26% | -28.85% | -8.23% | -27.15% | -13.12% | -49.84% | -51.06% |
| Total Other Income/Expenses | 968.00K | -8.93M | -13.83M | -1.50M | 181.00K | -12.13M | -2.54M | -19.46M | -1.00M |
| Income Before Tax | -134.70M | -466.71M | -136.43M | -55.42M | -17.14M | -53.04M | -19.64M | -75.70M | -40.64M |
| Income Before Tax Ratio | -43.56% | -156.33% | -51.07% | -29.65% | -8.15% | -35.20% | -15.07% | -67.09% | -52.35% |
| Income Tax Expense | 0.00 | -1.45M | -7.86M | 3.05M | 548.00K | -12.13M | 5.74M | 32.11M | -16.00K |
| Net Income | -134.70M | -465.26M | -128.57M | -58.47M | -17.69M | -53.04M | -19.64M | -75.70M | -40.63M |
| Net Income Ratio | -43.56% | -155.85% | -48.13% | -31.29% | -8.41% | -35.20% | -15.07% | -67.09% | -52.33% |
| EPS | -3.69 | -13.92 | -3.99 | -2.15 | -0.75 | -2.78 | -1.01 | -5.40 | -2.90 |
| EPS Diluted | -3.69 | -13.92 | -3.99 | -2.15 | -0.75 | -2.78 | -1.01 | -5.40 | -2.90 |
| Weighted Avg Shares Out | 36.49M | 33.42M | 32.20M | 27.21M | 23.75M | 19.06M | 19.52M | 14.03M | 14.03M |
| Weighted Avg Shares Out (Dil) | 36.49M | 33.42M | 32.20M | 27.21M | 23.75M | 19.06M | 19.52M | 14.03M | 14.03M |
Shareholders that Lost Money on Cardlytics, Inc.(CDLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - CDLX
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial...
The Schall Law Firm Is Looking Into Whether Cardlytics, Inc. Violated Securities Regulations And Shareholders Are Urged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations...
Shareholders that Lost Money on Cardlytics, Inc. (CDLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - CDLX
NEW YORK, NY / ACCESSWIRE / September 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial...
Cardlytics Inc May Have Defrauded Investors And Those With Losses Should Join The Schall Law Firm's Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK , Sept. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ: CDLX).
An Investigation Has Commenced on Behalf of Cardlytics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CDLX Losses.
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial...
The Schall Law Firm Is Looking Into Whether Cardlytics, Inc. Committed Securities Law Violations And Stockholders Are Invited To Take Part
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations...
Levi & Korsinsky Reminds Shareholders of an Investigation into Cardlytics, Inc. (CDLX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial...
Levi & Korsinsky Reminds Cardlytics Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CDLX
NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Source: https://incomestatements.info
Category: Stock Reports